Metformin
A long-established oral medication that supports insulin sensitivity and metabolic health.
- Insulin sensitivity and metabolic health
- Weight management as an adjunct
- Decades of real-world safety data
Indicative price · confirmed after eligibility · prescription treatment
What it does
Metformin has been in clinical use for decades, is one of the most-prescribed medications in the world, and has a safety record almost nothing in the longevity conversation can match.
That is precisely why it keeps coming up. In a field full of compounds with interesting mechanisms and thin human data, metformin is the opposite: enormous real-world experience, a well-understood profile, and an open question about whether it does anything beyond what it is approved for.
Metformin works mainly on insulin sensitivity — how effectively your cells respond to insulin. It reduces the amount of glucose the liver releases, and improves how muscle takes glucose up.
That matters in midlife more than most people realize. Insulin resistance develops gradually and silently, often years before blood sugar looks abnormal on a standard test, and it sits underneath a lot of what people experience as midlife metabolic change — weight that will not shift, energy dips after meals, stubborn central weight gain.
Metformin is a well-established oral medication used to support blood-sugar regulation and insulin sensitivity. In a weight-management context it is considered as an adjunct — on its own or alongside a GLP-1 — for eligible adults.
How it works here
Every plan follows one path. Each step feeds the next. See the Medical Weight Loss approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
Metformin or a GLP-1?
Different mechanisms, different magnitudes, and frequently not an either/or.
| Metformin | GLP-1 | Both together | |
|---|---|---|---|
| Available at ACT 2 | Yes | Yes | Yes |
| Main mechanism | Insulin sensitivity, hepatic glucose output | Appetite signaling and gastric emptying | Complementary |
| Effect on appetite | Modest | Substantial | Substantial |
| Route | Oral tablet | Injection or capsule | Both |
| Regulatory status | FDA-approved, dispensed as manufactured | Compounded | Mixed |
| Cost position at ACT 2 | Lowest in the weight line | Higher | Highest |
| Track record | Decades | Shorter | — |
| Best suited to | Insulin resistance is central; wanting a non-GLP-1 option; cost matters | Appetite is the main obstacle | Metabolic picture where both mechanisms apply |
Scroll the table sideways to compare →
The honest summary: these are not competitors. Metformin addresses insulin handling; a GLP-1 addresses appetite. If your labs point to insulin resistance, metformin may belong in the plan whether or not you are also on a GLP-1 — and it is the least expensive thing in the weight-management line by a wide margin.
What to monitor — including B12
Gastrointestinal effects are the most common issue — nausea, digestive upset, altered bowel habit. They often ease over time, and adjustments usually help. Tell your clinician rather than stopping.
Vitamin B12 warrants specific attention. Long-term metformin use is associated with reduced B12 absorption, and B12 monitoring is a recognized part of ongoing metformin care. Low B12 produces fatigue and, over time, nerve symptoms — which are easy to attribute to something else entirely. If levels do fall, that is addressable; B12 injections are one option, and the point is that it is checked rather than assumed.
Kidney function is checked before and during treatment, because metformin is cleared renally.
Rare but important: lactic acidosis is a well-known, uncommon risk, mainly in the context of significant kidney impairment, acute illness, dehydration or heavy alcohol use. Tell your clinician if you become unwell, and mention it before any procedure involving contrast imaging.
Who this is not right for
Not appropriate with significant kidney impairment, during acute illness with dehydration, or with a history of lactic acidosis. Heavy alcohol use is a genuine concern. Liver disease and unstable heart failure need review first.
Pregnancy and breastfeeding warrant a specific conversation rather than a general answer.
Delivery
An oral tablet, taken as directed by your clinician.
Is it right for you?
Adults 45+ managing weight and metabolic markers who want a non-GLP-1 option or an adjunct to one — particularly where lab work shows insulin resistance rather than a weight problem alone. Eligibility is determined by a clinician based on your history and goals, not a single diagnosis. See medical weight loss.
What else is worth considering
If you want to see how your metabolism actually responds day to day, a CGM makes that visible rather than inferred. And if longevity is your interest specifically, rapamycin is the other conversation — with considerably more risk and stronger animal evidence.
Metformin is the least expensive item in our weight-management line, and the price shown here is ongoing rather than one-off.
Often considered alongside
Semaglutide Injection
CompoundedA GLP-1 receptor agonist that works with your body's appetite and blood-sugar signaling to support weight management.
View treatmentTirzepatide Injection
CompoundedA dual GLP-1 and GIP receptor agonist that supports appetite regulation and weight management.
View treatmentB12 Injection
A vitamin B12 injection explored for energy support, often used within a broader plan.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
An honest word on the longevity evidence
Metformin appears constantly in longevity discussion, and the reasoning is worth understanding along with its limits. What prompted the interest: observational data suggesting people taking metformin for diabetes sometimes had better outcomes than expected, including in conditions unrelated to blood sugar. That is genuinely interesting — and observational data of that kind is prone to confounding, so it generates hypotheses rather than conclusions. Where it stands: the definitive trial designed to test whether metformin affects aging itself has been discussed for years and has not delivered an answer. So the honest position is that metformin is a well-established medication for metabolic health, with an unproven and plausible longevity hypothesis attached. One open question worth knowing about if you train: there is an active line of research asking whether metformin blunts some of the adaptations to exercise — the gains from resistance and aerobic training. It is not settled either way. We raise it because we tell people constantly that protecting muscle after 45 is the priority, and it would be inconsistent to leave out a question that bears directly on that. Worth discussing with your clinician if structured training is central to your plan.
References
Government and professional-society sources consulted for this page.
- Metformin — MedlinePlus (U.S. National Library of Medicine)
- Insulin Resistance & Prediabetes — National Institute of Diabetes and Digestive and Kidney Diseases
- Understanding Unapproved Use of Approved Drugs “Off Label” — U.S. Food and Drug Administration
Frequently asked questions
No. It works differently, mainly on insulin sensitivity, and is sometimes used alongside a GLP-1. Any weight effect is generally modest compared with a GLP-1.
Eligibility is determined by a clinician based on your history and goals, not a single diagnosis. Use for metabolic health outside an approved indication is off-label and considered case by case.
That is unproven. Observational data prompted the interest, but the trial designed to answer the question has not delivered one. Metformin is well established for metabolic health; the longevity hypothesis is plausible and unconfirmed.
Long-term use is associated with reduced B12 absorption, and B12 monitoring is a recognized part of metformin care. Low B12 causes fatigue and, over time, nerve symptoms — which is why it is checked rather than assumed.
There is an open research question about whether metformin blunts some adaptations to exercise. It is not settled. If structured training is central to your plan, it is worth discussing with your clinician.
Mostly gastrointestinal — nausea, digestive upset, altered bowel habit — often easing over time and usually improved with adjustment. Tell your clinician rather than stopping.
Often, yes. They work on different mechanisms and are frequently used together where the metabolic picture supports both.
Anyone with significant kidney impairment, acute illness with dehydration, or a history of lactic acidosis. Heavy alcohol use is a real concern, and liver disease or unstable heart failure need review first.
See if Metformin fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.